---
title: "CSPC PHARMA's innovative drug SYH2085 has been approved to conduct clinical trials"
description: "CSPC PHARMA announced that its developed Class 1 innovative chemical drug SYH2085 tablets have been approved by the National Medical Products Administration of China for clinical trials in China. The "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270403949.md"
published_at: "2025-12-21T12:01:54.000Z"
---

# CSPC PHARMA's innovative drug SYH2085 has been approved to conduct clinical trials

> CSPC PHARMA announced that its developed Class 1 innovative chemical drug SYH2085 tablets have been approved by the National Medical Products Administration of China for clinical trials in China. The approved clinical indication is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and older

CSPC PHARMA (01093.HK) announced that the Group's developed chemical Class 1 innovative drug SYH2085 tablets have been approved by the National Medical Products Administration of China to conduct clinical trials in China. The approved clinical indication is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and above

### Related Stocks

- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 中金公司維持對石藥集團（CHJTF）的買入評級 | 中金公司重申了對石藥集團（CHJTF）的買入評級，目標價為 12.00 港元。此外，TipRanks 也對該公司發佈了買入評級。然而，在同一天，TipRanks 將石藥集團的評級下調至持有 | [Link](https://longbridge.com/en/news/274393834.md) |
| 石藥集團獲得中國批准進行多個藥物試驗 | 石藥集團獲得中國多個藥物試驗的批准 | [Link](https://longbridge.com/en/news/270994613.md) |
| 巴拿馬港口｜長和啟動國際保障機制 要求當局磋商 斥馬士基接管構成損害 | 長和（001）就巴拿馬港口爭議通知巴拿馬，要求磋商並尋求解決方案。長和警告馬士基接管港口將造成損害，並可能引發法律行動。巴拿馬政府未提供港口運營保障，長和表示若港口特許經營權被迫終止，將無法繼續運營。巴拿馬海事管理局依賴馬士基成為港口臨時管 | [Link](https://longbridge.com/en/news/275768883.md) |
| 渣打 CFO 閃辭跳槽打擊大 股價續跌 分析︰過去為集團帶來倍數升幅「曾產生變革性影響 」 | 渣打銀行（2888）CFO 杜智高（Diego De Giorgi）突然離任，轉任阿波羅全球管理的歐洲、中東及非洲地區主管。此消息導致渣打股價大幅下跌，昨日收市跌 1.9%，今日再跌 0.9%。高盛分析認為此人事變動令人意外，可能影響 CE | [Link](https://longbridge.com/en/news/275577029.md) |
| 閲文 (772) 發盈警，新麗傳媒再 18 億商譽減損 | 閲文集團發布盈警，因新麗傳媒 18 億元商譽減損，預計 2025 年虧損 7.5 億至 8.5 億元。新麗傳媒利潤減少，扣除非經常性利潤將降至 8 至 9 億元。面對觀眾對高品質內容的期待，新麗傳媒將調整生產策略，控制創作節奏，提升內容品質 | [Link](https://longbridge.com/en/news/275543341.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.